Expert Commentary:
ICH is a devastating disease, and often one which we often must watch powerlessly, despite the acuity of presentation. One of the first goals in ICH management is to prevent further bleeding. Platelets for aspirin reversal seemed promising, since it has been documented that patients on aspirin have more hematoma expansion and worse outcomes, as well as clear anecdotal evidence from surgeons that platelet infusion in aspirin users makes an overt difference intra-op. So why should PATCH have been negative?
Given the complexity of factors leading to hematoma expansion and subsequent hospitalization, it is hard to drive outcomes with any one intervention. However, even the rate of hematoma expansion was unchanged. Even though the irreversible binding of Aspirin usually takes many days to wash out, serum half-life is about 15-20 minutes (with active metabolites lingering a few hours). One thing to remember is that transfused platelets themselves can have time-limited efficacy due to immune-related consumption and inactivation.
While even a temporarily effective transfusion can help stop brief bleeding such as in the OR or during acute stabilization, it is unlikely to prevent the stuttering hematomal expansion of ICH.
Platelets, unlike other blood products, must be stored at room temperature. Therefore, platelet transfusions are associated with high risks of transfusion reactions. It is theorized that some platelets may become activated prior to transfusion and can therefore also be associated with a risk of pathological clotting. These factors could blunt any potential benefit of treatment.
Intracerebral hemorrhage is a rarer and more heterogenous illness than stroke or MI. This trial is as high of quality as we are likely to obtain on the topic. When applying the results of the PATCH trial, it is important to remember that no patients with platelet counts below 100k were enrolled, so transfusions to meet that goal may still be performed. Also, it is still acceptable to transfuse for procedures or surgery. The study did not explore any sort of functional assays, namely Platelet Function Assay (PFA) or Platelet Aspirin Assay (PAA).
Stephen Trevick, MD
Neurocritical Care Fellow, NUEM
The PATCH Trial